Third, the considerable expression of Mecp2 in neural tissues warrants additional investigation into the potential efficacy of a combined approach involving Mecp2 and alpinetin in suppressing neuro‐inflammatory responses, consequently impeding the advancement of neurodegenerative disorders such as Alzheimer's and Parkinson's disease. This evidence concerns the gene MECP2 and Parkinson disease.